Preclinical efficacy of calcium nanoparticles adjuvanted influenza vaccines including H1N1 and H5N1


According to a presentation entitled “BioVant Calcium Phosphate (CaP) Nanoparticles: An Effective Safe Adjuvant for Influenza Vaccines including H1N1 and H5N1” given by BioSante Pharmaceuticals at the Immunotherapeutics & Vaccine Summit (ImVacS) last week : “BioSante’s vaccine adjuvant, BioVant™, increased the protective effect of vaccines for multiple flu strains, including a potential new vaccine against H1N1 (swine flu), which resulted in 100 percent protection from symptoms of illness, including weight loss, and death in animal studies.” More precisely the adjuvant “effectively enhanced the natural immune response to the swine flu, using a BioVant-adjuvanted matrix protein M1 vaccine, and to H5N1 (bird flu), using a BioVant- adjuvanted H5N1 vaccine delivered via intranasal administration.” (see the company’s full press release for other details). BioSante Pharmaceuticals now seemingly plans to license BioVant to a vaccine maker (see Reuters article).  

[[[ Additional links suggested by Nanocolors :

# Nano & vaccines in patents since 2000 ]]]

About these ads

8 Responses

  1. CaP often refered to nano particles attack the lungs of people and can be very deadly. There is abundant research to back this up showing that it can kill normally healthy people breaking down their immune system.

  2. Such an assertion without references / precise examples backing it up is weak… Hope you’ll present some for further discussion.

  3. So what about this?

    http://erj.ersjournals.com/cgi/content/full/34/3/559

    This is of course about much higher levels of nanoparticles, but they obviously travel through the body to places where they should not be and where they are harmful.

  4. Song Y, Li X, Du X, Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma , European Respiratory Journal, 9/2009, 34(3): 559-567.

    http://erj.ersjournals.com/cgi/content/short/09031936.00178308v1

    Nano Particles used in Untested H1N1 Swine Flu Vaccines

    http://www.globalresearch.ca/index.php?context=va&aid=15092

  5. Example, Andre > Indeed the European Respiratory Journal study you both mention is a very mediatized, recent report on cases of clinical toxicity in humans linked to nanoparticles. Very interesting comments about it from Andrew Maynard and other experts can be found at :

    http://2020science.org/2009/08/18/new-study-seeks-to-link-seven-cases-of-ocupational-lung-disease-with-nanoparticles-and-nanotechnology/

    and

    http://2020science.org/2009/08/18/nanoparticle-exposure-and-occupational-lung-disease-six-expert-perspectives-on-a-new-clinical-study/

    Andre > The other article you propose also refers to this same publication.

    From a personal point of view I would say the properties of nanoparticles (and also here their potential interactions with living organisms) very much depend on their specific chemical nature and shape. There are very diverse types of manufactured nanoparticles (for example made of gold, ZnO, TiO2, silver, CaP… etc) and it is (scientifically) not possible to draw general conclusions from a particular case.

    Two other points seem important to me :
    – vaccines against the H1N1 flu were developped in a very short time ; a significant number of health professionals do not recommend the use of the vaccines (wether they contain nanoparticle-based adjuvants or not) because they consider clinical data are stil insufficient (to date, low number of patients tested, and no perspective about possible long-term side effects,…).
    – research about nanotech risks is still far behind research about nanotech applications ; one illustration of this fact is the comparison between the total volume of nanotech-related biomedical publications (see http://nanocolors.wordpress.com/2009/02/14/volumetry-of-nanotech-related-biomedical-publications-since-2000/) and the volume of publications explicitly dealing with nanotech risks (see http://nanocolors.wordpress.com/2009/03/01/risks-associated-to-nanotechnologies-volumetry-of-biomedical-publications-since-2000/ ).

  6. I agree there is just a small number of articles about dangers of nanotechnology and little examples to give – but that just underscores the point that the research regarding the safety of nanotech products is very limited. Even commonly used nanoparticles and their effects (typically, nano-silver and TiO2) are not very well known once released in to the body.

    Therefore, one can only wonder (but we do not have real data/experiments to know) – e.g. if vaccine uses nanotechnology adjuvants to deliver them to lymph nodes or whereever needed, what happens when these particles get to other places within one’s body such as brain. Does something happen or not? Do we get problems from one vaccine or after ten or twenty vaccines with nano-adjuvant? What happens with them within the body, what are critical masses triggering some more serious reaction etc.

  7. I agree with you on the fact that lots of efforts are still to be done in research about the safety of nanotech products and in the investigation of the benefit/risk balance (especially concerning health, environmental and ethical issues) of the already existing various nanotech applications.

  8. […] Pharmaceuticals now seemingly plans to license BioVant to a vaccine maker (see Reuters article). Nanocolors, 8/24/09 The article that has been associated with the claim on nanoparticles in the H1N1 Swine Flu […]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

%d bloggers like this: